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Abstract
The outcome of stroke patients is complex and multidimensional. We evaluated the impact
of acute-phase variables, including clinical state, complications, resource use and interven-
tions, on 6-month survival after first-ever stroke, taking into account baseline conditions
exerting a possible effect on outcome.
As part of a National Research Program, we performed a prospective observational
study of acute stroke patients in four Italian Regions. Consecutive patients admitted for a
period of 3 months to the emergency rooms of participating hospitals were included.
A total of 1030 patients were enrolled (median age 76.0 years, 52.1% males). At 6
months, 816 (79.2%) were alive, and 164 (15.9%) deceased. Survival status at the 6-month
follow-up was missing for 50 (4.9%). Neurological state in the acute phase was significantly
worse in patients deceased at 6 months, who showed also higher frequency of acute-phase
complications. Cox regression analysis adjusted for demographics, pre-stroke function,
baseline diseases and risk factors, indicated as significant predictors of 6-month death
altered consciousness (HR, 1.70; 95% CI, 1.14–2.53), total anterior circulation infarct (HR,
2.13; 95% CI, 1.44–3.15), hyperthermia (HR, 1.70; 95% CI, 1.18–2.45), pneumonia (HR,
1.76; 95% CI, 1.18–2.61), heart failure (HR, 2.87; 95% CI, 1.34–6.13) and nasogastric feed-
ing (HR, 2.35; 95% CI, 1.53–3.60), while antiplatelet therapy during acute phase (HR, 0.56;
95% CI, 0.39–0.79), and early mobilisation (HR, 0.55; 95% CI, 0.36–0.84) significantly
increased 6-month survival.
In a prospective observational study, stroke severity and some acute-phase complica-
tions, potentially modifiable, significantly increased the risk of 6-month death, independently
of baseline variables. Early mobilisation positively affected survival, highlighting the role of
early rehabilitation after stroke.
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Introduction
The outcome of stroke patients is complex and multidimensional, and depends on a number of
pre-stroke and acute-phase variables. Baseline determinants include demographics,[1,2] vascu-
lar risk factors,[3,4] pre-existing comorbidities and functional status.[5] Considering acute-
phase determinants, some are intrinsic to the stroke event itself, such as clinical and pathological
types, which influence the severity of presentation.[6,7] Others depend on the interventions and
procedures specifically adopted in the different settings,[8,9] as well as on the occurrence of
stroke-related complications during hospitalisation. Complications during the acute phase
include both medical and neurological complications. They influence length of hospital stay,
access to rehabilitation, survival, functional outcome and overall costs of stroke care.[10,11]
So far, studies on stroke outcome have often evaluated the role of single acute-phase vari-
ables,[8,9,12–14] reporting on their frequency and effect on clinical course, while a more
global framework of acute-phase variables with a potential impact on long-term outcome, tak-
ing also into account the role of baseline pre-stroke determinants, is lacking.
Implementation of evidence-based interventions in stroke care is receiving increasing
attention, due to the perceived necessity to narrow the gap between research findings and
everyday practice.[15]
The Emilia-Romagna Region, supported by the Italian Ministry of Health, coordinated the
National Research Program: “Taking charge of stroke patients: implementation of integrated
pathways of care and management tools”. The Program included a prospective observational
study in four Italian Regions. The present research aims to evaluate the impact of acute-phase
variables on survival 6 months after a first-ever stroke, taking into account baseline conditions
exerting a possible impact on the selected outcome.
Methods
Study design
We performed a prospective observational study on stroke care in Italy in 19 hospitals located
in four Regions of Northern and Central parts of the country: Emilia-Romagna, Toscana,
Umbria and Lazio. All hospitals had an emergency department and a minimum of 50 acute
stroke patients discharged per year; five were university hospitals, the remaining were large
community hospitals having a wide range of specialties and providing advanced diagnostic
procedures (e.g., magnetic resonance diagnostics).
Starting from November 1st, 2012, and for the subsequent 3 months, all consecutive
patients admitted to the emergency rooms of participating hospitals with a confirmed diagno-
sis of first-ever stroke were included. Exclusion criteria were age<18 years, in-hospital stroke,
and death within 24 hours of admission.
Stroke was defined according to World Health Organization,[16] and classified into cerebral
infarction, primary intracerebral haemorrhage, and subarachnoid haemorrhage, based on at
least one of the following: brain imaging (CT/MRI) performed within 30 days of stroke onset,
cerebrospinal fluid analysis, or necropsy examination. Cases without subtype confirmation
were unspecified stroke. Following the Oxfordshire Community Stroke Project criteria,[17]
ischemic stroke subtypes were classified as total anterior circulation infarct (TACI), partial ante-
rior circulation infarct (PACI), posterior circulation infarct (POCI) or lacunar infarct (LACI).
Data collection
Specially trained physicians collected data in participating hospitals during the acute-phase
(defined as length of stay in the ward of admission before discharge home, to rehabilitation
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ward, long-term care, or in-hospital death), and at the 6 months follow-up. To minimize
across units and interobserver variability, a centralised training was organized to explain
research design and study protocol to fieldworkers. Standardized protocols for case-ascertain-
ment were provided, and common data collection tools were used. Problems occurring during
data collection were discussed with the coordinating centers (Bologna and Florence). Data
gathering was performed through structured questionnaires directly from the patient/family
and hospital records. Fieldworkers had access to the dataset but were not aware of planned
analyses. Information was collected on the following variables:
1. Baseline characteristics: age, sex, living conditions (home alone, with others, in institution),
education, pre-stroke functional status evaluated with the modified Rankin scale,[18] and
drug usage before stroke.
2. Vascular risk factors and comorbid conditions: hypertension (previous diagnosis, current
treatment, or values140/90 mmHg in at least 2 subsequent measurements), previous
myocardial infarction, cardiac valvular disease, atrial fibrillation (medical history and/or
positive ECG), heart failure, diabetes mellitus (previous diagnosis or on diabetic medica-
tion), hypercholesterolemia, smoking (current or former), peripheral artery disease, and
transient ischemic attack.
3. Clinical state: neurological examination and assessment of clinical severity, evaluated with
the National Institutes of Health Stroke Scale (NIHSS).[19] The NIHSS score was catego-
rized into three classes: 0–5 (low severity), 6–13 (moderate severity), and>13 (high sever-
ity). This categorization was based on previous analyses of stroke severity in relation to
outcome from population-based studies and clinical trials.[20,21]
4. Complications during acute phase: hyperglycaemia (glucose level>10 mmol/L, 180 mg/
dL), hyperthermia (body temperature over 38˚C), pneumonia (diagnosed by the treating
physician, based on the presence of respiratory infection symptoms or signs, laboratory test
and radiological evidence), pulmonary embolism, urinary retention, urinary tract infection
(clinical symptoms and urine sample positive for nitrite, leucocyturia, and significant bacte-
riuria), heart failure (diagnosed by a cardiologist considering symptoms, signs, electrocardi-
ography, chest X-ray, echocardiography), myocardial infarction, deep vein thrombosis
(ultrasonography, with examination of the deep, superficial, and common femoral and pop-
liteal veins), pressure ulcers, seizures.
5. Diagnostic tests (brain imaging, carotid duplex scan, transcranial Doppler, transthoracic
and transoesophageal echocardiogram), resource use and treatments during hospitalisa-
tion, including early mobilisation (out-of-bed performed activities: sitting, sit-to-stand
transfers, standing and walking) of patients within 48 hours of stroke onset, and length of
hospital stay.
Functional status at discharge was evaluated using the Barthel Index,[22] with the following
categorization: moderately or severely dependent (0–74), mildly dependent (75–84), indepen-
dent85.[23]
The 6-month follow-up questionnaire was administered through a face-to-face (patient still
in hospital or in outpatients clinic) or telephone direct or proxy interview. The study was
approved by the ethics committee of the S. Orsola-Malpighi Hospital in Bologna, the national
coordinating center, on February 14th 2012, Code 47/2012/O/Oss. Patients were evaluated for
altered consciousness, cognitive or language deficits. Written informed consent was given
directly by patients in absence of deficits, or by legal representatives or family members
according to institutional guidelines.
Acute-phase predictors of 6-month stroke survival
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Statistical analysis
Continuous variables are presented as median and 1st and 3rd quartiles, categorical variables as
proportions. The chi-square test was used to compare categorical variables, and the Mann-
Whitney U test for continuous variables. Cox proportional hazard models evaluated the inde-
pendent effect of acute-phase variables on the risk of death 6 months after stroke. Hazard ratio
(HR) and 95% confidence intervals (95% CI) were calculated. All variables showing statistically
significant differences in univariate analysis, including demographics, pre-stroke function,
baseline diseases and risk factors, were entered in the multivariate analyses, performed using a
forward stepwise method (P entry = 0.05, P removal = 0.10). Intercorrelation was tested in
order to avoid collinearity. All P-values were based on a 2-sided test and a significance level of
< .05.
Kaplan-Meier estimates and log-rank statistics evaluated cumulative risk of death at 6
months. Survival time was measured starting from date of stroke onset to death within the fol-
low-up period for deceased patients. Survivors were censored at their date of follow-up inter-
view. Analyses were performed using IBM-SPSS (Statistical Package for the Social Sciences),
Version 23.0 (Armonk, NY: IBM Corp.).
Results
During the study period, 1030 patients with first-ever stroke were enrolled in participating
hospitals [median age 76.0, (65.9–82.9) years; 52.1% males]. At 6 months 816 (79.2%) were
alive, and 164 (15.9%) deceased. Information on survival status was missing for 50 patients
(4.9%), which had complete baseline assessment, and were not significantly different from fol-
lowed patients considering age [median age 79.9, (73.1–83.5) vs. 75.8 (65.6–82.9) years,
P = 0.107 ], sex (males, 50.0% vs. 52.2%, P = 0.757), stroke severity (NIHSS distribution 0–5,
58.0%, 6–13, 28.0%,>13, 14.0%, vs. 51.6%, 27.2%, and 21.2%, respectively, P = 0.239). Survival
was not significantly different between the 2 types of hospitals (84.1% in university hospitals
vs. 82.9% in large community hospitals, P = 0.660).
Table 1 reports the frequency of baseline variables by survival status at follow-up.
Survivors were younger, less often institutionalized prior to stroke, and with a higher edu-
cation level. Among comorbidities, hypertension, atrial fibrillation and heart failure were sig-
nificantly more frequent at baseline in deceased patients, as well as a higher level of prestroke
functional deficits assessed by the modified Rankin scale. Prior to stroke antihypertensive,
antiplatelet and anticoagulant therapy was also significantly more often reported in deceased
patients.
Median length of acute stay was 9 (6–12) days in survivors and 10 (6–16) days for deceased
patients (P = 0.010). Table 2 indicates that acute-phase clinical state was significantly more
severe in patients deceased at 6 months.
They showed significantly more often altered consciousness, motor and visual field deficits,
aphasia, dysphagia and urinary incontinence. NIHSS score was also significantly higher in
deceased patients. Intracerebral haemorrhage was significantly more frequent in deceased
patients, as well as a diagnosis of TACI among the clinical syndromes of ischemic stroke.
Complications in the acute phase are reported in Table 3.
Those occurring with significantly higher frequency in deceased patients were hyperglycae-
mia, hyperthermia, pneumonia, urinary retention, urinary tract infections, heart failure, pres-
sure ulcers and seizures.
Table 4 reports resource use and interventions in acute phase.
Significantly more frequent in patients deceased at 6 months were nasogastric feeding and
urinary catheterization, while significantly more frequently used in survivors resulted MRI,
Acute-phase predictors of 6-month stroke survival
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carotid and transcranial Doppler, transthoracic and transoesophageal echocardiograms. Anti-
platelets and cholesterol lowering drugs were also more significantly often used in survivors, as
well as intravenous and intra-arterial thrombolysis. Early mobilisation was reported in 51.1%
of survivors and in 20.1% of patients deceased at 6 months (P<0.001).
The role of NIHSS on functional status and survival at discharge was also evaluated. In sur-
vivors, 26.2% of patients scoring 0–5 at NIHSS were in the Barthel Index group scoring 0–74,
4.8% in the group scoring 75–84, and 69.0% in those scoring85. Of patients in the NIHSS
category 6–13, 68.6% were in the Barthel Index group scoring 0–74, 6.2% in the group scoring
75–84, and 25.2% in those scoring85. Considering patients in the NIHSS>13 category,
88.5% were in the Barthel Index group scoring 0–74, 2.7% in the group scoring 75–84, and
8.8% in those scoring85 (P for trend <0.001).
In patients deceased at 6 months, but alive at discharge, 68.2% of patients scoring 0–5 at
NIHSS were in the Barthel Index group scoring 0–74, 9.1% in the group scoring 75–84, and
22.7% in those scoring85. All patients in NIHSS categories 6–13 and>13 were in the Barthel
Index group scoring 0–74 (P for trend<0.001).
Considering patients scoring 0–5 at NIHSS, 1.6% deceased during the acute phase,
compared with 3.9% of patients scoring 6–13, and 19.8% of those scoring >13 (P for
trend<0.001).
Cox regression analysis evaluating the independent effect of acute-phase variables on sur-
vival, adjusted for demographics, pre-stroke function, baseline diseases and risk factors, and
including indicators of stroke severity such as NIHSS and stroke subtypes, indicated that sig-
nificant predictors of 6 months death were altered consciousness, TACI, hyperthermia, pneu-
monia, heart failure and nasogastric feeding, while performing MRI, antiplatelet therapy and
Table 1. Distribution of baseline variables among survivors and deceased at 6 months from acute stroke.
Variable Survivors
n = 816
Deceased
n = 164
P Total sample
n = 980
Median age (1st-3st quartiles), y 74.4 (64.0–81.6) 82.7 (76.8–88.1) <0.001 75.8 (65.6–82.9)
Sex (males) 53.2% 47.6% 0.188 52.2%
Living at home alone 20.2% 15.0% 0.130 19.3%
Living at home with others 78.9% 79.4% 0.905 79.0%
Institutionalized 0.9% 5.6% <0.001 1.7%
High school level or higher 26.0% 12.8% <0.001 23.8%
Hypertension 73.9% 87.2% <0.001 76.1%
Previous myocardial infarction 11.2% 15.2% 0.139 11.8%
Cardiac valvular disease 6.4% 9.1% 0.199 6.8%
Atrial fibrillation 17.4% 31.7% <0.001 19.8%
Heart failure 3.3% 8.5% 0.002 4.2%
Diabetes 20.6% 24.4% 0.277 21.2%
Hypercholesterolemia 36.4% 22.0% <0.001 34.0%
Current or previous smoking 50.8% 46.2% 0.330 50.1%
Peripheral artery disease 5.8% 9.1% 0.104 6.3%
Transient ischemic attack 7.0% 7.3% 0.880 7.0%
Antihypertensive therapy 64.3% 79.3% <0.001 66.8%
Antiplatelet therapy 36.2% 45.1% 0.031 37.7%
Anticoagulant therapy 7.2% 14.6% 0.002 8.5%
Antidiabetic drugs 16.2% 18.3% 0.506 16.5%
Cholesterol lowering drugs 22.5% 19.5% 0.392 22.0%
Pre-stroke modified Rankin 3–5 5.3% 26.3% <0.001 8.7%
https://doi.org/10.1371/journal.pone.0194786.t001
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early mobilisation in acute phase significantly increased the probability of survival at follow-up
(Table 5).
To control for a possible “indication/reversal causality” effect, i.e. increased probability of
patients with minor events to receive antiplatelet therapy and early mobilisation in acute
phase, we performed a subgroup analysis for the three NIHSS classes of severity. The role of
antiplatelets was confirmed for patients in the NIHSS group 0–5, (HR, 0.37, 95% CI, 0.17–
Table 2. Clinical state at time of maximum impairment among survivors and deceased at 6 months from acute stroke.
Variable Survivors
n = 816
Deceased
n = 164
P Total sample
n = 980
Altered consciousness 9.8% 46.7% <0.001 15.7%
Motor deficits 66.8% 85.5% <0.001 69.7%
Visual field deficits 19.4% 42.2% <0.001 23.0%
Aphasia 30.8% 59.2% <0.001 35.3%
Dysarthria 31.0% 24.5% 0.120 30.0%
Dysphagia 23.2% 62.2% <0.001 29.7%
Urinary incontinence 8.6% 22.0% <0.001 10.8%
NIH Stroke Scale <0.001 —
0–5 57.7% 19.7% 51.6%
6–13 28.2% 21.7% 27.2%
>13 14.1% 58.6% 21.2%
Stroke pathological type
Ischemic stroke 84.9% 69.5% <0.001 82.3%
Intracerebral haemorrhage 12.8% 26.8% <0.001 15.1%
Subarachnoid haemorrhage 1.7% 2.5% 0.529 1.9%
Unspecified stroke 0.6% 1.2% 0.400 0.7%
Syndromes of ischemic stroke
TACI 7.5% 31.1% <0.001 11.4%
PACI 39.6% 18.9% <0.001 36.1%
POCI 15.3% 9.1% 0.039 14.3%
LACI 16.0% 4.3% <0.001 14.1%
Unspecified ischemic stroke 6.5% 6.1% 0.850 6.4%
 P for trend
https://doi.org/10.1371/journal.pone.0194786.t002
Table 3. Complications in acute phase among survivors and deceased at 6 months from acute stroke.
Variable Survivors
n = 816
Deceased
n = 164
P Total sample
n = 980
Hyperglycaemia 3.3% 9.1% 0.001 4.3%
Hyperthermia 10.4% 39.6% <0.001 15.3%
Pneumonia 5.3% 24.4% <0.001 8.5%
Pulmonary embolism 0.4% 0.6% 0.657 0.4%
Urinary retention 2.3% 6.1% 0.009 3.0%
Urinary tract infections 7.7% 17.1% <0.001 9.3%
Heart failure 1.0% 6.7% <0.001 1.9%
Myocardial infarction 0.2% 1.2% 0.074 0.4%
Deep vein thrombosis 3.2% 1.8% 0.349 3.0%
Pressure ulcers 2.9% 9.8% <0.001 4.1%
Seizures 1.8% 7.9% <0.001 2.9%
https://doi.org/10.1371/journal.pone.0194786.t003
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0.80; P = 0.012), and the positive effect of early mobilisation for patients in the NIHSS group
6–13 (HR, 0.41, 95% CI, 0.18–0.94; P = 0.034), and>13 (HR, 0.46, 95% CI, 0.22–0.98;
P = 0.045). More detailed information is provided in S1 Table.
We also evaluated possible predictors of ischemic or haemorrhagic stroke in two models of
Cox regression analysis. For ischemic stroke, significant predictors of 6-month survival were
essentially coincident with those found for total sample, as shown in Table 6.
Stroke severity, as evaluated with NIHSS, was a major predictor of outcome in haemorrha-
gic stroke, together with heart failure and modified diet (Table 7).
Fig 1 shows the Kaplan-Meier survival curves for patients with or without acute-phase vari-
ables predictive of outcome (all log-rank tests P<0.001).
Table 4. Resource use and interventions during hospitalisation among survivors and deceased at 6 months from acute stroke.
Variable Survivors
n = 816
Deceased
n = 164
P Total sample
n = 980
Stroke unit admission 60.0% 59.8% 0.944 60.0%
Modified diet 19.1% 17.1% 0.541 18.8%
Nasogastric feeding 8.5% 51.2% <0.001 15.6%
Percutaneous endoscopic gastrostomy 0.9% 0.6% 0.747 0.8%
Urinary catheterization 27.9% 65.2% <0.001 34.2%
Deep vein thrombosis prophylaxis 33.5% 43.9% 0.011 35.2%
CT scan 91.3% 94.5% 0.170 91.8%
MRI 40.2% 13.4% <0.001 35.7%
Carotid duplex scan 68.4% 47.6% <0.001 64.9%
Transcranial Doppler 24.0% 7.9% <0.001 21.3%
Transthoracic echocardiogram 44.4% 26.8% <0.001 41.4%
Transoesophageal echocardiogram 8.6% 3.0% 0.015 7.7%
Antiplatelet therapy 67.4% 46.3% <0.001 63.9%
Oral anticoagulant therapy 12.7% 10.4% 0.398 12.3%
Cholesterol lowering drugs 37.6% 15.2% <0.001 33.9%
Insulin 7.1% 11.6% 0.052 7.9%
Intravenous thrombolysis 15.1% 4.9% <0.001 13.4%
Intra-arterial thrombolysis 2.5% 0.0% 0.043 2.0%
Carotid endarterectomy 2.2% 0.6% 0.176 1.9%
Carotid angioplasty and stenting 1.7% 1.8% 0.919 1.7%
Early mobilisation 51.1% 20.1% <0.001 45.9%
https://doi.org/10.1371/journal.pone.0194786.t004
Table 5. Acute-phase variables as predictors of 6-month mortality after stroke. Cox regression analysis adjusted
for demographics, pre-stroke function, baseline diseases and risk factors. Total sample.
Variable P HR (95% CI)
Altered consciousness 0.009 1.70 (1.14–2.53)
TACI <0.001 2.13 (1.44–3.15)
Hyperthermia 0.005 1.70 (1.18–2.45)
Pneumonia 0.005 1.76 (1.18–2.61)
Heart failure 0.006 2.87 (1.34–6.13)
Nasogastric feeding <0.001 2.35 (1.53–3.60)
MRI 0.018 0.55 (0.34–0.90)
Antiplatelet therapy 0.001 0.56 (0.39–0.79)
Early mobilisation 0.005 0.55 (0.36–0.84)
https://doi.org/10.1371/journal.pone.0194786.t005
Acute-phase predictors of 6-month stroke survival
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Discussion
In a prospective survey of 980 patients hospitalised for first-ever stroke, we evaluated the role
of acute-phase variables on survival 6 months after the acute event. Controlling for baseline
variables with a possible influence on outcome, we found that stroke severity and acute-phase
complications of hyperthermia, pneumonia, heart failure and necessity of nasogastric feeding
all increased the risk of death 6 months after stroke. Improved survival was instead associated
with some acute-phase interventions: performing MRI, use of antiplatelets during hospitalisa-
tion, and early mobilisation of patients.
Sixty percent of our patients were admitted to a stroke unit. In Italy, stroke patients are
mainly admitted to general medicine wards, neurological wards, stroke units and geriatric
wards. On a national basis, only about one third of total stroke patients are currently admitted
to stroke units. The percentage, although still unsatisfactory, is higher in Northern and Central
Italy, where are located more than 85% of Italian stroke units.[15] The outcome of patients
admitted to stroke units was not significantly different considering patients admitted to other
medical wards. However, a stroke unit was present in all but four of the hospitals included in
our survey. Therefore, a treatment contamination effect may not be excluded when comparing
different wards of the same hospital, with a potential dissemination of stroke units methods to
the other medical wards.
Altered consciousness in acute phase reflects the severity of the stroke event, and is among
the most recognized predictors of death.[24] The diagnosis of TACI is also related to a higher
severity of stroke. Larger infarcts are more prone to edema development and hemorrhagic
transformation,[25] and have also been associated with the presence atrial fibrillation,[6]
another indicator of a worse prognosis.[3] A shorter survival in patients with TACI was
reported in several surveys on stroke outcome.[6,24] Our study confirmed also the well-
known role of NIHSS in predicting acute-phase and long-term mortality, particularly in
patients with intracerebral haemorrhage.[26,27]
In the first days of stroke, hyperthermia occurs in up to 30–40% of patients, and it is inde-
pendently associated with poor outcome and increased mortality.[28] In our patients,
Table 6. Acute-phase variables as predictors of 6-month mortality after ischemic stroke. Cox regression analysis
adjusted for demographics, pre-stroke function, baseline diseases and risk factors.
Variable P HR (95% CI)
Altered consciousness 0.004 1.99 (1.25–3.17)
Hyperthermia 0.001 2.08 (1.34–3.25)
Pneumonia 0.001 2.16 (1.37–3.40)
Nasogastric feeding <0.001 4.16 (2.58–6.71)
MRI 0.018 0.53 (0.31–0.90)
Antiplatelet therapy 0.001 0.49 (0.32–0.75)
Early mobilisation 0.019 0.55 (0.33–0.91)
https://doi.org/10.1371/journal.pone.0194786.t006
Table 7. Acute-phase variables as predictors of 6-month mortality after intracerebral haemorrhage. Cox regres-
sion analysis adjusted for demographics, pre-stroke function, baseline diseases and risk factors.
Variable P HR (95% CI)
NIHSS 0.001
NIHSS 6–13 (ref. 0–5) 0.148 2.43 (0.73–8.08)
NIHSS >13 (ref. 0–5) <0.001 5.35 (2.21–12.93)
Heart failure 0.011 7.48 (1.60–34.94)
Modified diet 0.007 0.17 (0.05–0.61)
https://doi.org/10.1371/journal.pone.0194786.t007
Acute-phase predictors of 6-month stroke survival
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multivariate analysis showed that hyperthermia during acute phase increases the risk of death
by 70%. Hyperthermia eight hours after stroke onset was related to a poor outcome at 3
months in the Virtual International Stroke Trials Archive (VISTA),[29] with a similar increase
in the risk (HR, 1.7; 95% CI, 1.2–2.2), and it increased mortality by 50% in a meta-analysis
including 14 431 patients with stroke and other brain injuries.[30]
Pneumonia is widely recognized among most frequent medical complications after stroke,
with incidence ranging between 1% and 44%,[31] depending on clinical settings and heteroge-
neity of surveys. Stroke-associated pneumonia is thought to be secondary to aspiration and
immunological alterations, part of the stroke-induced immunodepression.[32]
Although in our sample we had a low frequency of pneumonia (8.5%), this complication
occurred 5 times more frequently in patients deceased at 6 months, and increased the risk of
mortality at follow-up by 76% after multiple adjustments. In other surveys, stroke patients
with pneumonia showed significantly higher mortality than those without after 3 months,[33]
and one year from the acute event.[34]
Dysphagia is a frequent complication after stroke, reported in percentages ranging between
37% and 78% according to different surveys, probably reflecting wide differences in case-mix,
study design and ascertainment.[35] Stroke patients with dysphagia are at increased risk of
undernutrition and dehydration.[10] Dysphagia also significantly increases the risk of pneu-
monia,[35] disability, death and institutional care.[36] Modified diet and nasogastric feeding
are used to meet nutritional requirements of dysphagic stroke patients: respective frequencies
in our deceased patients were 17.1% and 51.2%. Only nasogastric feeding was selected in total
sample and ischemic stroke as significant predictor of outcome in multivariate Cox regression,
indicating that the effect on survival was probably explained by a different degree in the sever-
ity of dysphagia, while a beneficial effect of the modified diet was found in patients with intra-
cerebral haemorrhage.
In the first months from stroke, 2% to 6.2% of patients die from cardiac causes,[37] which
include acute myocardial infarction, heart failure, ventricular tachycardia/fibrillation, and car-
diac arrest.[38] Despite a potentially high impact on outcome, the role of heart failure has been
specifically evaluated only by few studies. In the VISTA dataset, heart failure, diabetes, high
baseline creatinine, severe stroke and a long QTc or ventricular extrasystoles on ECG were
predictors of severe cardiac events in the acute phase of stroke.[38] In a series of 813 consecu-
tive stroke patients, acute-phase heart failure was reported in 5%. At 3 months after stroke,
62.5% of patients with acute heart failure were dead, vs. 16.5% of patients without heart failure.
[39] In our study, acute-phase heart failure occurred in 1.9% of patients. At follow-up, 57.9%
of patients with acute heart failure were dead, vs. 15.9% of stroke patients without (P<0.001).
The effect of heart failure on survival was shown in total sample and in patients with a diagno-
sis of intracerebral haemorrhage. These data suggest the need for a careful evaluation, moni-
toring and management of cardiac complications after stroke.
In a recent survey of 6 regional or national stroke quality registers in Europe, brain and vas-
cular imaging are among performance measures selected as indicators of quality of care, and
possibly effective in influencing outcome.[40] However, we are very cautious about the prog-
nostic value of MRI on outcome. Although studies showed higher sensitivity of MRI in detect-
ing acute stroke,[41] in routine practice MRI is often used for detecting lesions in suspected
stroke when CT scan results are inconclusive, as is the case for small ischemic lesions, which
carry a more favourable outcome.[42] In our study MRI was performed in 20.5% of TACI and
in 38.4% of LACI patients (P = 0.002). Moreover, median NIHSS was 4 (2–7) in patients with
MRI performed and 7 (3–14) in patients without MRI (P<0.001).
The role of early started antiplatelet therapy in improving survival and functional outcome
of ischemic stroke patients, by reducing the volume of ischemic lesion and preventing early
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recurrent ischemic stroke, is well established.[9] In our survey this effect was evidenced in
total sample, in ischemic stroke and in less severe stroke as evaluated with NIHSS.
Early mobilisation after stroke is recommended by many guidelines, although they do not
specify how soon after onset or how much therapy is best, largely due to insufficient evidence.
[43] Advantages of early mobilisation include reduction of medical complications,[44] while a
decrease of cerebral blood flow in critically hypoperfused regions with altered vasoregulation
might explain the potentially harmful effects.[45]
Fig 1. Kaplan-Meier survival estimates within 6 months after stroke onset according to acute-phase variables
predictive of outcome (total sample).
https://doi.org/10.1371/journal.pone.0194786.g001
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While phase II results of A Very Early Rehabilitation Trial (AVERT) showed benefits of
very early and intensive mobilisation after stroke on functional outcome at 3 months,[46] final
results of the trial showed that the higher dose and very early mobilisation protocol was associ-
ated with reduced odds of a favourable functional outcome at 3 months.[47] In the AVERT,
92% of patients were mobilised within 24 hours in the very early mobilisation group, com-
pared with 59% of the usual care group. In our survey, percentages were more close to the
usual care group, with 46% of patients receiving early mobilisation in a longer time period of
48 hours from stroke onset. Our study adds information to the still limited evidence of early
mobilisation after stroke, showing a significantly positive effect on 6-month survival after con-
trolling for baseline and acute-phase variables. This effect was confirmed in subgroup analyses
for stroke severity defined according to NIHSS score in 6–13 and>13 classes of severity.
A number of prognostic scales are available in stroke medicine, focused mainly on mortality
or disability after the acute event.[48] The IScore,[49] the Acute Stroke Registry and Analysis
of Lausanne (ASTRAL) Score,[50] the modified-Stroke subtype, Oxfordshire Community
Stroke Project classification, Age, and prestroke modified Rankin (mSOAR),[51] are among
the tools with the higher prognostic accuracy.
The IScore includes age, sex, stroke severity, stroke subtype, smoking status, preadmission
dependency, and the presence or absence of atrial fibrillation, heart failure, previous myocar-
dial infarction, cancer, renal failure on dialysis, and hyperglycemia on admission. The
ASTRAL Score includes as predictors of outcome age, severity of stroke measured with the
NIHSS, stroke onset to admission time, range of visual field defect, acute glucose and level of
consciousness. Variables included to calculate mSOAR were age, stroke subtype (based on
clinical and neuroimaging finding), Oxfordshire Community Stroke Project classification, pre-
stroke modified Rankin Scale, and baseline NIHSS at the time of first assessment on hospital
arrival.
The majority of these variables were assessed in our multivariate analyses, and some were
included in our final models, although we found a prognostic role for some other acute-phase
complications and interventions, such as pneumonia, hyperthermia, acute-phase heart failure
and early mobilisation. Our predictors of stroke outcome are easily collected in common clini-
cal practice, considering that the routine use of prognostic scales is often limited by their com-
plexity or requirement of information not always available in the acute setting.[48] Accurate
prediction of stroke outcome may guide physicians in treatment decision, and provide reliable
information when counseling patients and their families.
Our survey has strengths and limitations. Among the strengths there is the prospective
design, the short duration of enrolment, without changes in existing routine clinical practice,
the large sample size and the multicentre approach. Data were collected during hospital admis-
sion by a small group of trained health professionals. To increase the homogeneity of data
recording, a manual was provided to each research unit, and meetings were organized to stan-
dardize procedures. Information on survival at the 6-month follow-up was available for over
95% of patients. Studies on early complications of stroke were often focused on acute phase,
while data on their impact on long-term outcome are scarce. Moreover, our study evaluated
the role of multiple acute-phase variables, controlling also for baseline determinants, including
demographics, vascular risk factors, pre-existing comorbidities and functional status. Among
limitations there is the lack of inclusion of other acute-phase variables with a possible effect on
outcome, and the possible variation of case-mix among hospitals, although we believe that, by
including general and university hospitals, our sample may be considered representative of
current stroke care in Northern and Central Italy.
In conclusion, in a prospective survey of patients hospitalised for first-ever stroke, control-
ling for baseline variables possibly influencing outcome, we found that stroke severity and
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some acute-phase complications, potentially modifiable, although not completely avoidable,
significantly increased the risk of death at 6 months. Among acute-phase interventions, early
mobilisation showed a positive effect on survival, adding information to the still limited evi-
dence on the role of very early rehabilitation after stroke.
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